-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
CGBio’s Novosis Achieves Bone Union in All Seven Patients in Scaphoid Nonunion Study
CGBio announced Friday that its bone graft substitute, Novosis, achieved bone union in all seven patients participating in a preliminary clinical study for scaphoid nonunion. The results, derived from a study conducted at Yonsei University Wonju College of Medicine, suggest the treatment may serve as a viable alternative to traditional autologous bone grafting, which requires harvesting bone from the patient’s own body.
CGBio, a regenerative medicine company, announced Friday that its bone graft substitute Novosis achieved bone union in all seven patients enrolled in a preliminary clinical study for scaphoid nonunion. The treatment was administered alongside screw fixation, and the results indicate the product’s potential as an alternative to autologous bone grafting.
The clinical investigation was conducted by a research team from the Department of Orthopedic Surgery at Wonju Severance Christian Hospital, affiliated with Yonsei University Wonju College of Medicine. The study was led by Professors Park Ji-soo, Kwon Ki-youn, Ahn Hyung-joon, and Oh Jin-rok. Their findings were published in the international journal Orthopaedic Surgery under the title "Clinical and Radiologic Outcomes of NOVOSIS Grafting for Scaphoid Waist Nonunion: A Preliminary Clinical Study."
The scaphoid is one of eight small bones in the wrist, playing a critical role in wrist movement and stability. Due to its limited blood supply, fractures in this bone carry a high risk of nonunion, a condition where the fractured bone fails to heal properly. Delayed or ineffective treatment can result in chronic pain, wrist deformity, impaired mobility, and eventual wrist arthritis.
Standard surgical intervention for scaphoid nonunion typically involves harvesting autologous bone from the patient’s pelvis or the area surrounding the wrist. This procedure requires an additional incision, extends operating time, and can lead to complications such as pain or sensory abnormalities at the donor site.
Between August 2023 and December 2024, the research team treated seven patients diagnosed with scaphoid waist nonunion using Novosis combined with fixation via two compression screws. The participants had a mean age of 30 years, and surgery was performed an average of 11.5 months after the initial injury. The mean follow-up period for the study was 12.4 months.
The study included only patients in whom stable screw fixation was possible and who did not suffer from severe avascular necrosis or advanced collapse. Consequently, the effectiveness of Novosis-based surgery in such severe cases was not established within this trial.
Novosis used in the procedures consisted of 0.5 mg of recombinant human bone morphogenetic protein-2 (rhBMP-2) and a porous hydroxyapatite (HA) carrier. After removing fibrous tissue and sclerotic bone from the nonunion site, researchers implanted Novosis and stabilized the fracture with two compression screws. No additional autologous or allogeneic bone graft was utilized.
The primary outcome indicated that at the end of the follow-up period, all seven patients had achieved bone union. Radiographic confirmation of union occurred in most patients approximately three to four months after surgery.
One patient, who had previously undergone surgery with an iliac crest autograft but experienced persistent nonunion and loosening of fixation screws, underwent revision surgery. During this procedure, Novosis was used without an additional autologous bone graft, resulting in complete bone union within six months.
Pain levels and wrist function improved significantly across the cohort. The mean Visual Analog Scale (VAS) pain score decreased from 4.9 before surgery to 0.4 after surgery. The mean Mayo Wrist Score, which evaluates wrist pain, function, range of motion, and grip strength, increased from 59.3 to 94.3.
Post-surgery assessments showed that grip strength recovered to approximately 87.5 percent of that of the unaffected hand, while wrist range of motion recovered to about 89 percent. All seven patients reported satisfaction with the reduction in pain and improvement in function.
Radiographic assessments also demonstrated improved carpal alignment. The lateral intrascaphoid angle, an indicator of scaphoid deformity, improved from a mean of 51.7 degrees before surgery to 31.5 degrees after surgery. The scapholunate angle, which reflects alignment between the scaphoid and lunate bones, decreased from 65.7 degrees to 52.2 degrees.
No major complications, including infection, screw loosening, or heterotopic ossification (bone forming in unintended locations), were observed during the follow-up period. Because no autologous bone was harvested, there were also no donor-site complications such as pain or nerve injury.
Novosis is a bone graft substitute that combines rhBMP-2, which induces new bone formation, with an HA carrier that serves as a scaffold for bone growth. It is designed to provide both osteoinductive and osteoconductive properties.
The researchers stated that the findings demonstrate Novosis can achieve reliable bone union and functional recovery in scaphoid nonunion cases, potentially reducing the burden associated with autologous bone grafting. The study is significant for extending clinical evidence for Novosis, previously accumulated mainly in spine and long bone applications, to small wrist bones with limited blood supply.
The researchers cautioned that the study was a retrospective preliminary investigation involving only seven patients and lacked a control group. They noted that larger prospective comparative studies are necessary to establish the treatment's long-term safety and efficacy.
"The scaphoid is a small bone with limited blood supply, making nonunion particularly difficult to treat, so it is very encouraging that all patients treated with Novosis in this study achieved bone union and meaningful functional recovery," CGBio CEO Yu Hyun-seung said.
Yu added, "Most importantly, the findings demonstrate the potential to support bone regeneration while reducing patients’ pain and surgical burden without the need to harvest a separate autologous bone graft."
"We will continue to build clinical evidence for Novosis not only in the spine and long bones but also across a wide range of bone regeneration applications, including the hand and foot, and expand its clinical value so that more patients can regain their everyday function," Yu said.
W.Nelson--AT